A Novel RNAi Lethality Rescue Screen to Identify Regulators of Adipogenesis by van Beekum, Olivier et al.
A Novel RNAi Lethality Rescue Screen to Identify
Regulators of Adipogenesis
Olivier van Beekum
1., Yuan Gao
1., Ruud Berger
1, Arjen Koppen
1, Eric Kalkhoven
1,2*
1Department of Metabolic Diseases, Netherlands Metabolomics Centre, University Medical Centre Utrecht, Utrecht, The Netherlands, 2Centre for Molecular and Cellular
Intervention, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands
Abstract
Adipogenesis, the differentiation of fibroblast-like mesenchymal stem cells into mature adipocytes, is tightly regulated by a
complex cascade of transcription factors, including the nuclear receptor Peroxisome proliferator activator receptor c
(PPARc). RNAi-mediated knock down libraries may present an atractive method for the identification of additional
adipogenic factors. However, using in vitro adipogenesis model systems for high-throughput screening with siRNA libraries
is limited since (i) differentiation is not homogeneous, but results in mixed cell populations, and (ii) the expression levels
(and activity) of adipogenic regulators is highly dynamic during differentiation, indicating that the timing of RNAi-mediated
knock down during differentiation may be extremely critical. Here we report a proof-of-principle for a novel RNAi screening
method to identify regulators of adipogenesis that is based on lethality rescue rather than differentiation, using microRNA
expression driven by a PPARc responsive RNA polymerase II promoter. We validated this novel method through screening
of a dedicated deubiquitinase knock down library, resulting in the identification of UCHL3 as an essential deubiquitinase in
adipogenesis. This system therefore enables the identification of novel genes regulating PPARc-mediated adipogenesis in a
high-throughput setting.
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Introduction
The relationship between obesity and its complications, such as
type 2 diabetes and cardiovascular diseases, has firmly established
adipose tissue as a key regulator of glucose and lipid metabolism
[1]. Adipose tissue regulates metabolism through at least two
different mechanisms: the storage of lipids (as triglycerides) and the
secretion of so-called adipokines, which function in an endocrine
or paracrine fashion. Expansion of adipose tissue, as seen in obese
individuals, not only affects the storage of lipids as triglycerides in
lipid droplets, but also results in qualitative and quantitative
changes in a number of adipokines [2]. The amount of mature
adipocytes is largely determined by the differentiation of
fibroblast-like mesenchymal stem cells into adipocytes, a process
called adipogenesis [1,3]. One of the best-established model
systems for adipogenesis is the mouse 3T3-L1 cell line, which can
efficiently be differentiated into mature adipocytes by hormonal
stimulation under experimental conditions [4,5]. Adipogenesis is
regulated by a cascade of transcription factors, ultimately leading
to the induction of the transcription factor Peroxisome proliferator
activator receptor c (PPARc) [1,6]. Several independent lines of
investigation have led to the qualification of PPARc as the master
regulator of adipogenesis. For example, in vitro differentiation of
fibroblasts into mature adipocytes can be induced by introduction
of PPARc [7]. In addition, this protein regulates a large set of
‘‘adipocyte genes’’, involved in lipid and glucose metabolism, in a
feed-forward loop with another transcription factor, C/EBPa
[8,9]. Furthermore, PPARc
2/2 mice are severely lipodystrophic,
while PPARc
+/2 mice have reduced amounts of adipose tissue
[10,11,12,13]. PPARc is also essential for the maintenance of
adipose tissue, since conditional knock-out of the Pparg gene
resulted in reduced in vivo survival of mature adipocytes [14].
Finally, human Familial partial lipodystrophy subtype 3 (FPLD3,
MIM 604367) patients, harbouring heterozygous mutations in the
PPARG gene, are characterized by aberrant fat distribution and
metabolic disturbances, including insulin resistance and dyslipide-
mia [15]. Besides PPARc, other proteins are also essential for
adipogenesis, including transcription factors (e.g. KLF5 [16]),
transcriptional co-regulators (e.g. TRAP220/Med1 [17], Tip60
[18], TLE3 [19] and TRIP3 [20]) and lipid droplet proteins (e.g.
CIDEC/Fsp27 [21]). These essential adipogenic factors have been
identified through various means, such as in vivo studies [16,22],
yeast 2-hybrid screening [17], peptide interaction assays [20],
cDNA library high-throughput-screening [19] and co-immuno-
precipitations followed by mass spectrometry [18]. Furthermore,
phenotypic screening resulted in the identification of the small
molecules harmine and phenamil as novel PPARc-targeting
compounds [23,24].
Since the discovery of siRNA as a way to specifically down-
regulate gene expression, a broad spectrum of siRNA libraries
have been developed that are now widely used in discovering
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playing part in various cellular processes [25]. Recent findings
indicate that this technology presents an attractive alternative and
complementary method for the identification of novel regulators in
adipogenesis. Tang et al. employed a small 96 well-scale siRNA
library screen to identify protein kinases involved in inhibition of
insulin induced glucose uptake in fully differentiated 3T3L1
adipocytes. From this screen the integrin-linked protein kinase
MAP4K4 was identified as a negative regulator of adipogenesis
supressing expression of the adipogenic transcription factors C/
EBPa, C/EBPb and PPARc [26].
However, while 3T3-L1 cells present one of the best-established
models for adipogenesis, screening for novel adipogenic regulators
in these cells presents several (potential) problems. First, 3T3-L1
differentiation is not homogeneous, but results in mixed cell
populations, with various degrees of differentiation
[27,28,29,30,31]. This, together with the genetic variation
observed in these cells [32], may result in a high false discovery
rate. Second, the expression levels (and activity) of adipogenic
regulators is highly dynamic during differentiation [3,6], indicating
that the timing of RNAi-mediated knock down during differen-
tiation may be extremely critical. We therefore developed a novel
screening method to identify regulators of adipogenesis that makes
use of a U2OS cell line stably expressing PPARc, instead of 3T3-
L1 cells. This method is primarily based on loss of blasticidin
resistance via PPARc-driven microRNA expression, with the
additional advantage that overexpression of PPARc may inhibit
U2OS cell growth, as observed in other cell lines [33]. In
conclusion this system uses lethality rescue rather than differen-
tiation as a read-out method, thereby allowing the identification of
novel genes regulating adipogenesis in a high-throughput fashion.
Results
PPARc2 Driven miRNA Expression Results in Loss of
Blasticidin Resistance
While vector-based siRNA techniques generally employ RNA
polymerase III-driven expression [34], Stegmeier et al. recently
reported efficient knock-down of gene expression from RNA
polymerase II-driven miR30 miRNA-based vectors. [35]. This was
achieved by replacing the region encoding the mature miR30
miRNA with sequences that encode shRNAs targeting a gene of
choice. Amongst others, this system was tested using two pPRIME
(potent RNA interference using microRNA expression) vectors
expressing different miRNAs directed against firefly luciferase
mRNA, named FF2 and FF3. Based on these vectors, we
developed a novel screening method depicted here as ‘‘RNAi
lethality rescue screening’’ (Fig. 1).
For our subsequent studies we used the human U2OS
osteosarcoma cell line, since these cells (i) are easy to handle and
transfect, (ii) express a robust transcriptional response upon
introduction of PPARc, both on the level of reporter genes
[36,37] and endogenous target genes (data not shown), and (iii)
may be growth inhibited by activation of PPARc, a phenomenon
also observed in multiple other cell lines [33,38] which will support
lethality rescue screening. We first tested whether miRNA FF2,
originally directed against luciferase mRNA, could target a
heterologous transcript. For this, 3 firefly luciferase sequences
recognized by miRNA FF2 were fused to the 39 UTR of the
blasticidin resistance cassette, which encodes a Blasticidin S
deaminase gene (bsd from Aspergillus terreus). Next, U2OS cells
underwent retroviral transduction with a vector encoding this
CMV promoter-driven blasticidin-36FF2 cassette and stable
clones were selected with Blasticidin S (Fig. 2A). To test whether
constitutive miRNA FF2 expression resulted in loss of resistance,
these cells were subsequently transduced with a miRNA FF2
expressing retrovirus, under control of either the RNA polymerase
II-driven CMV promoter or the RNA polymerase III-driven U6
promoter. Cells expressing miRNA FF2 driven by either RNA
polymerase II or RNA polymerase III showed a significant loss of
blasticidin resistance (Fig. 2A). As a control, empty virus or non-
specific miRNA FF3 expressing virus were used, and neither
resulted in significant loss of blasticidin resistance. From these
experiments we conclude that this system allows efficient
expression of miRNAs by RNA polymerase II and III promoters.
Furthermore, the FF2 targeting sequences, originally from the
firefly luciferase gene, can be transferred to a heterologous
blasticidin resistance gene, resulting in significant loss of expression
of this gene when exposed to the miRNA-based FF2 vector.
PPARc2 Dependent miRNA Expression
Next we investigated whether the constitutively active CMV
promoter, driving miRNA FF2 expression, could be replaced by a
PPARc2 responsive promoter (see also Fig. 1). We first isolated
U2OS cells stably transduced with a 36PPRE miRNA FF2 virus.
The resulting U2OS 36PPRE miRNA FF2 stable cell line
underwent a second round of retroviral transduction to express
Blasticidin S deaminase and PPARc2 (Fig. 2B). When these two
viruses were used at a ratio of 1:10 respectively, activation of
PPARc by rosiglitazone had no effect on the blasticidin resitance.
However, when PPARc expression was increased by shifting the
ratio 36PPRE FF2-Blasticidin: PPARc2 to 1:25, a significant loss
of resistance for Blasticidin S was observed in the presence of
1 mM rosiglitazone (Fig. 2C). These experiments indicate that
miRNA-FF2 expression from the 36PPRE-miRNA-FF2 vector
can be induced by rosiglitazone in cells expressing sufficient
amounts of PPARc2, resulting in loss of blasticidine resistance
conferred by the blasticidine-36FF2 cassette.
To verify whether the effect of PPARc2-driven miRNA
expression on loss of blasticidine resistance is indeed mediated
by PPARc2, we knocked-down PPARc2 expression by siRNA
technology. Different shRNA expression vectors directed against
PPARc were generated and transiently expressed in U2OS
36PPRE miRNA FF2 cells. As shown in Figure 3A (upper panel),
siRNA vector #4 efficiently knocked-down the expression of
PPARc, while vectors #1–3 were less efficient, as assesed by
Western blotting. Next, U2OS 36PPRE miRNA FF2 cells were
transiently transfected with the different PPARc siRNA expression
vectors and incubated in the presence of rosiglitazone. After
selection with Blasticidin S for 1 week in the presence of
rosiglitazone (1 mM), colonies were visualized with Giemsa
staining. As shown in Figure 3A (lower panel), the functional
PPARcsiRNA expression vector #4 could partially rescue the loss
of blasticidine resistance observed upon activation of PPARc by
rosiglitazone. Loss of blasticidin resistance was only partially
rescued by considerable knock down of PPARc activity, suggesting
that the screening method filters out mainly strong activators of the
PPARc pathway. The 3 shRNA vectors which gave no efficient
knock-down of PPARc expression (#1, #2 and #3) also failed to
rescue blasticidine resistance (Fig. 3A), indicating that the loss of
blasticidin resistance in the presence of rosiglitazone shown in
Figure 2B is indeed mediated by PPARc. To corroborate these
findings, FACS analysis was performed on the same cells with
different concentrations of Blasticidin. For this we developed a
retroviral GFP vector expressing the functional siRNA #4
directed against PPARc2 described above. U2OS 36PPRE
miRNA FF2 cells were stably transduced and selected at different
concentrations of Blasticidin S for 1 week. The percentage of GFP
RNAi Screen to Identify Adipogenesis Regulators
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GFP postive cells after Blasticidin S selection increased approx-
imately three fold in case of siRNA induced PPARc2 knock down
while it remained unchanged in empty GFP vector transduced
cells (Fig. 3B). Taken together, these experiments indicate that the
loss of resistance in U2OS 36PPRE miRNA FF2 induced by
rosiglitazone is dependent on PPARc2 expression.
RNAi Lethality Rescue Screening Identifies UCHL3 as a
Regulator of Adipogenesis
Post-translational modifications (PTM), such as phosphoryla-
tion, acetylation, sumoylation and ubiquitination, can regulate the
transcriptional output of adipogenic transcription factors like C/
EBPa and PPARc (reviewed in [39,40]). Since the role of
deubiquitylating enzymes in adipogenesis has not been studied
extensively yet, we used an shRNA library that targets deubiqui-
tinating enzymes (DUBs) [41] to validate our screening system.
Four shRNA knockdown vectors against each DUB were pooled
into 24 sets, where each set targets a single DUB transcript (see
Table S1). The U2OS 36PPRE miRNA FF2 cells were selected
by Blasticidin S in the presence of 1 mM rosiglitazone after siRNA
vector electroporation. After 3 weeks of culture, colony formation
was only observed when the expression of Ubiquitin Carboxyl-
terminal Hydrolase isozyme L3 (UCHL3) or UCHL5 was
reduced, while for example knock down of the closely related
UCHL1 enzyme did not result in colony formation (Fig. 4A).
To further investigate the potential role of UCHL3 in
adipogenesis, we first examined its protein expression and
localization in 3T3-L1 cells. As is shown in Figure 4B, the
expression levels of UCHL3 increased during 3T3-L1 differenti-
ation. Next, we examined the subcellular localisation of UCHL3 in
mature 3T3-L1 adipocytes. In agreement with other cell types
[42,43,44], UCHL3 displayed cytoplasmatic localization in 3T3-
L1 adipocytes (Fig. 4D). Finally, we addressed the relevance of
UCHL3 in adipogenesis using two different approaches. First,
UCHL3 enzymatic activity was determined, using an HA-tagged
ubiquitin probe. This probe is recognized by active DUBs, after
Figure 1. Schematic model of miRNA mediated siRNA screening. The upper panel illustrates the situation of cells with active PPARc2-
mediated gene expression. PPARc drives miRNA FF2 expression, resulting in repression of the Blasticidin S deaminase expression cassette via the
target repeat FF2 sequences present in the 39 UTR. The lower panel depicts the situation of cells with an siRNA mediated knock-down of a PPARc2
activating protein. Expression of the FF2 miRNA is diminished and Blasticidin S deaminase expression is no longer repressed, resulting in blasticidin
resistance.
doi:10.1371/journal.pone.0037680.g001
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irreversibly binds DUBs [45,46]. Immunoprecipitation of active
DUBs from mature 3T3-L1 adipocytes using anti-HA antibodies
followed by Western blotting with UCHL3 antibodies showed that
UCHL3 is an enzymatically active DUB in mature adipocytes
(Figure 4D). To address the relevance of UCHL3 in adipogenesis,
the expression of this protein was reduced. Adipogenesis was
inhibited by lentiviral short hairpin constructs against UCHL3
(shUCHL3 #14, 15 and 16), as illustrated by triglyceride staining
with Oil-red-O (Fig. 4E) and PPARc and FABP4 expression
(Fig. 4F). The degree of inhibition correlated with the reduction in
UCHL3 protein expression, with shUCHL3 #14 being the most
efficient and shUCHL3 #15 displaying a partial effect, and
underscores the importance of UCHL3 in 3T3-L1 adipocyte
differentiation. Taken together, our findings indicate that novel
regulators of adipogenesis can be identified by the RNAi lethality
rescue screening method described here.
Discussion
To identify novel regulators of adipogenesis, we have developed
an RNAi lethality rescue screen. This method is based on cell
survival, which is accomplished through inhibition of the
adipogenic transcription factor PPARc, resulting in blasticidin
resistance and possibly inhibition of PPARc-mediated growth
arrest [33]. A cell survival-based method has the advantage over,
for example reporter based screening methods, that it can
Figure 2. A RNA polymerase II and RNA polymerase III driven
miRNA FF2 expression results in loss of Blasticidine resistance.
U2OS cells expressing the Blasticidin 36FF2 expression cassette were
transduced with miRNA FF2 expressing virus and selected (50 mg/ml
Blasticidin S) for 1 week. As a control either empty virus or not FF2
specific miRNA FF3 virus was used, the latter expressing miRNA not
targetting the modified 39UTR of the blasticidin S deaminase gene. B.
PPARc2 expression compared to empty vector control as detected in
the stably transfected U2OS cell line also expressing the blasticidin
36FF2 expression cassette C. U2OS cells stably transduced with 36PPRE
miRNA FF2 virus were retransduced with blasticidin 36FF2 virus and
PPARc2 virus at a ration of 1:10 or 1:25 respectively. Cells transduced at
a ratio of 1:25 show loss of resistance when incubated in 1 mM
rosiglitazone and increasing amounts of Blasticidin S.
doi:10.1371/journal.pone.0037680.g002
Figure 3. A siRNA-mediated knock down of PPARc rescues
miRNA FF2 mediated loss of blasticidin resistance. Different
PPARc specific siRNA vectors were generated and tested for their ability
to rescue the loss of blasticidin resistance. The functional siRNA vector
#4 rescues the miRNA FF2 induced loss of resistance. B. The U2OS
36PPRE miRNA FF2 cells were partially rescued with PPAR#4 siRNA
expressing GFP virus. The percentage of GFP positive cells was
determined using FACS analysis after 1 week of blasticidin selection
at various concentrations.
doi:10.1371/journal.pone.0037680.g003
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Validation of the RNAi lethality rescue screen described here
enabled us to identify UCHL3 as a regulator of PPARc-mediated
differentiation of 3T3-L1 preadipocytes. In agreement with this,
Uchl3
2/2 MEFs were very recently shown to display impaired
adipocyte differentiation and lipid accumulation [47]. Morever,
Uchl3
2/2 mice displayed a reduction of adipose tissue mass and
were protected against high-fat diet-induced obesity and insulin
resistance [47,48]. Together with the current study, these findings
strongly support a critical role for UCHL3 in adipogenesis, both in
Figure 4. A, Small siRNA DUB screen perfomed in U2OS 36PPRE miRNA FF2 cells. A partial siRNA library against 24 different
deubiquitinating enzymes was tested for the ability to rescue the miRNA FF2 induced loss of Blasticidin resistance. Knock down of UCHL3 and UCHL5,
but not UCHL1, resulted in colony formation. B. UCHL3 expression increases during 3T3-L1 adipocyte differentiation. Mouse 3T3L1 preadipocytes
were differentiated into mature adipocytes and samples were taken at different time points during differentiation. Protein expression levels of UCHL3
were determined by Western blot analysis. As control for differentiation Fabp4 protein levels were analysed. C. UCHL3 activity in 3T3-L1 adipocytes.
Cell lysates of differentiated 3T3-L1 cells (day 6) were incubated with or without HA-Ub probe, DUB activities were immunprecipitated (anti-HA
agarose) and UCHL3 was detected by Western blotting. Note the difference in mobility between unmodified UCHL3 (input lane) and UCHL3
covalently bound to the DUB probe. An aspecific band is indicated (*). D. Localization of UCHL3 in differentiated 3T3-L1 cells. Nuclei were stained with
DAPI, UCHL3 was visualized by indirect immunofluorescence. Merged pictures demonstrate the predominant cytoplasmic localization of UCHL3. As a
control, the primary antibody was ommited. Bar, 10 mm. E. 3T3-L1 cells, stably transduced with lentiviral constructs expressing short hairpin RNAs
directed against UCHL3 or control shRNA, were subjected to differentiation conditions. At day 10 of differentiation, cells were fixed and stained for
triglycerides using Oil-red-O. Pictures are representative for three independent experiments. F. 3T3-L1 cells were stably transduced with either control
or UCHL3 shRNA and differentiated as described under E. Cell lysates were subjected to Western blot analysis, using antibodies against UCHL3,
PPARc, FABP4 and tubulin.
doi:10.1371/journal.pone.0037680.g004
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adipogenesis may not be limited to its ubiquitin hydrolase activity,
as this protein has dual specificity for ubiquitin and Nedd8, a
ubiquitin-like protein in vitro [49,50] and in vivo [51]. Like other
post-translational modifications, neddylation can alter substrate
function and activity by inducing conformational changes, or by
preventing or inducing protein-protein interactions [52]. The
critical deubiquitination and/or deneddylation substrates of
UCHL3 in adipogenesis remain to be established. Suzuki et al.
have shown that UCHL3 enhances insulin signalling in (pre)-
adipocytes, but UCHL3 is unlikely to target critical components of
insulin signalling like the insulin receptor, the IGF-I receptor, IRS-
1 and Grb10 [47]. Interestingly, these authors also observed
impaired expression of the late adipogenic genes fabp4, adiponectin
and srebp1c, three direct target genes of PPARc [8,53,54], in
Uchl3
2/2 MEFs and epididymal WAT of Uchl3
2/2 mice [47].
Ectopic expression of UCHL3, but not the catalytic mutant C95S,
restored expression of these genes in Uchl3
2/2 MEFs [47].
Together with the screening method presented here, which is
based on PPARc activity, these findings suggest that PPARc may
be a direct target for UCHL3. However, in agreement with other
studies [42,43,44], we found UCHL3 to be localized in the
cytoplasm, while PPARc was exclusively nuclear in mature 3T3-
L1 adipocytes. In addition, recombinant UCHL3 failed to
deubiquitinate PPARc in vitro (Figure S1 and Materials and
Methods SI), indicating that UCHL3 modulates PPARc activity
by an indirect mechanism, either through its ubiquitin hydrolase
or its deneddylase activity.
Taken together, we have developed and validated a novel RNAi
screen, based on PPARc induced growth arrest and loss of
resistance. This screening method was validated on a small scale
using an shRNA library targeting different deubiquitinating
enzymes. From these initial screens we identified UCHL3 as a
regulator of adipogenesis. In the future PPARc-mediated RNAi
lethality rescue screening may allow high throughput screening of
pooled RNAi libraries. The modules of this system can also readily
be exchanged for other reporters and/or expression vectors,
including heterologous reporters in combination with fusions of
protein domains (Gal4, LexA) (Fig. 1). Modified forms of this
lethality rescue screening method may therefore present a more
generic tool to identify regulatory proteins in fundamental cellular
processes.
Materials and Methods
Materials
RNAiMax was purchased from Invitrogen (Carslbad, USA).
The following antibodies were used: anti-PPARc (sc-7273), Santa
Cruz Biotechnologies; anti-UCHL3 (3525), Cell Signalling Tech-
nology; anti-tubulin (ab6046) Abcam; anti-rabbit-HRP
(111035144) and anti-mouse-HRP (115035146), Jackson Immu-
noresearch Laboratories Inc.; mouse anti-rabbit Alexa488, Invi-
trogen. The vinyl methyl ester HA-DUB probe (HAUbVME) was
generated and used as described [45].
Plasmids
The retroviral expression plasmid pMSCV-mPPARc2 (puro)
was a kind gift from Dr. B.M. Spiegelman [55]. The pPrime
miRNA expression CMV miRNA FF2 and FF3 vectors were a
kind gift from the Elledge lab and used for subsequent cloning
[35]. Target sequence with a mismatch at the first base for FF2;
cCCGCCTGAAGTCTCTGATTAA and for FF3;
aGCTCCCGCTGAATTGGAATCC. A BglII-HindIII fragment
encompassing the 36PPRE-TK promoter was digested from the
36PPRE-TK-luciferase reporter and subcloned into pLNCX
DClaI. The miRNA FF2 cassette was digested from pPrime using
ClaI, NotI and subcloned behind the 36PPRE-TK promoter to
generate the pLNCX 36PPRE FF2miRNA retroviral vector. A
SV40 polyA signal oligo was ligated at the 39 end of the FF2
cassette, using a ClaI site. All recombinant DNA work was
performed according to standard procedures [56]. All mutations
were generated by Quickchange mutagenesis (Stratagene) and
verified by sequencing.
Cell culture and Differentiation Assays
The human osteosarcoma cell line U2OS (ATCC, Manassas,
VA) and the Phoenix amphotropic packaging cell line (Allel
Biotechnology, San Diego, CA) were maintained in DMEM
Glutamax (Dulbecco) containing 10% foetal calf serum (Gibco
Life Technologies), 100 mg/ml penicillin and 100 mg/ml strepto-
mycin (Gibco Life Technologies). Electroporations of U2OS cells
were performed with the Biorad Genepulser Xcell using 2 mg
plasmid DNA and 100 ul cell suspension in electroporation buffer
(2 mM Hepes pH 7.2, 15 mM K2PO4/KH2PO4, 250 mM
Manitol and 1 mM MgCl2 pH 7.2) per electroporation, with
two times 8 pulses at 140 V, 1.5 msec burst duration at intervals of
1.5 s.
After 1 week of Blasticidin S selection at different concentrations
(0, 5, 10 and 50 mg/ml) cells were either fixed and subjected to
Giemsa staining or trypsinized and subsequently used for FACS
analysis. After brief centrifugation cells were resuspended in ice
cold PBS. The percentage of GFP positive cells of the total cell
population was determined after counting 10.000 cells using a
FACScan (Becton Dickinson, Biosciences).
Lentivirusses for transduction of UCHL3 short hairpin
constructs were generated in HEK293T cells using the MissionH
system (Sigma-Aldrich). As control the pLKO.1-puro Non-
Mammalian shRNA Control plasmid (SHC002) was used. After
lentiviral transduction, shRNA expressing cells were selected by
puromycin selection. Differentiation of shRNA expressing 3T3-L1
cells, Oil-red-O staining and Western blotting were performed as
described [18,20].
Immunofluorescence
For immunofluorescence staining, 3T3-L1 cells were plated on
glass coverslips. Cells were differentiated for 5 days, fixed with 4%
paraformaldehyde for 20 min RT and permeabilized in PBS
supplemented with 0.5% Triton for 10 min. After 30 min
incubation in blocking buffer, cells were stained with primary
antibodies for 2 h at RT, then incubated with secondary
fluorochrome-conjugated antibodies. After several washes, cover-
slips were mounted in Dabco-DAPI and analyzed with an
LSM710 Met confocal microscope (Carl Zeiss, Jena, Germany).
Supporting Information
Figure S1 UCHL3 fails to deubiquitinate PPARc in
vitro. HEK293T cells were transfected with HA-tagged PPARc
expression construct together with histidine-tagged ubiquitin (His-
ubi) expression construct and treated with MG132 (3 mM).
Ubiquitinated proteins were isolated by Ni-NTA precipitation,
eluted from the Ni-NTA beads with imidazole and incubated with
recombinant UCHL3 enzyme. Ubiquitinated PPARc was detect-
ed by Western blotting (anti-HA antibody).
(DOCX)
Table S1 Deubiquitinases tested in screening proce-
dure.
(DOCX)
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